Neumora Therapeutics (NMRA) Cash from Investing Activities (2022 - 2026)

Neumora Therapeutics' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at $71000.0 for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 99.84% year-over-year to $71000.0; the TTM figure through Mar 2026 stood at $124.4 million (up 0.67% YoY), while the FY2025 annual figure was $168.5 million, up 338.84% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $71000.0, down from $42.6 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $157.0 million in Q3 2024, with the low at -$150.0 million in Q1 2024.
• The 5-year median for Cash from Investing Activities is $22.5 million (2023), against an average of $11.0 million.
• Peak annual rise in Cash from Investing Activities reached 559.2% in 2024, while the deepest fall reached 5424.85% in 2024.
• Neumora Therapeutics' Cash from Investing Activities stood at -$8.0 million in 2022, then jumped by 270.32% to $13.7 million in 2023, then slumped by 822.37% to -$98.8 million in 2024, then jumped by 143.16% to $42.6 million in 2025, then tumbled by 99.83% to $71000.0 in 2026.
• Business Quant data shows NMRA's Cash from Investing Activities at $71000.0 in Q1 2026, $42.6 million in Q4 2025, and $51.3 million in Q3 2025.